



Celldex Therapeutics, Inc.
 Investor Relations Department
 119 Fourth Avenue
 Needham, MA 02494-2725
 United States

Visit IR website [↗](#)
 Sign-up for email alerts [↗](#)

| | |
|----------------------------------|--|
| NASDAQ: CLDX ¹ | |
| Last Trade: | 2.66 |
| Trade Time: | 4:00 PM ET Sep 22, 2017 |
| Change: | 0.20 ▲ (8.130%) |
| Day Range | 2.44 - 2.68 |
| 52-Week Range | 2.20 - 5.02 |
| Volume | 1,398,987 |
| Market Cap. (\$M) | 341.384 |
| Shares Out (M) | 128.340 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 22, 2017
[Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 12, 2017
[Celldex Announces Departure of Chief Medical Officer](#)
- Aug 23, 2017
[Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer](#)
- Aug 8, 2017
[Celldex Reports Second Quarter 2017 Results](#)
- Aug 2, 2017
[Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call](#)

Events [\[View all \]](#)

- Sep 26, 2017 11:30 AM ET
[Cantor Fitzgerald Global Healthcare Conference](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 14, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Definitive Proxy Statement](#)
- Aug 8, 2017
[Quarterly Report \(10-Q\)](#)
- May 9, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016
[Quarterly Report \(10-Q\)](#)